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This year marks the 20th anniversary of the publication of
Gruentzig’s landmark work in development of percutaneous
transluminal coronary angioplasty (PTCA) (1). In the 20
years since its inception, angioplasty has evolved from a
crude, often unsuccessful, often dangerous intervention to a
mainstay in the treatment of symptomatic coronary artery
disease (2). As an early observer and investigator of this
technique, I marvel at the extraordinary advances that have
occurred over the last two decades. At its inception, angio-
plasty was performed by skilled but inexperienced operators,
working with crude fluoroscopic images, no replay capability
and crude, bulky, rigid, nonsteerable catheters. It is little
wonder that even with stringent selection of soft, short,
concentric lesions in proximal vessels, only a 64% success
rate was achieved (3).
I can clearly recall performing angioplasty on a patient in
1983 and observing a major non–flow-limiting dissection in
the dilated vessel. I called numerous colleagues (including
Dr. Hartzler and Dr. Gruentzig) to seek advice on whether
the patient would require an urgent operation and whether
coronary aneurysm or rupture would occur in the convales-
cent phase. No one had definitive answers on how to treat
this patient. In the early 1980s these types of questions often
arose. The early operators were not only hampered by
inadequate equipment but also by a dearth of data with
which to make important decisions. Despite these short-
comings, the field of angioplasty rapidly evolved. A few
committed, intrepid investigators pushed the field of angio-
plasty and carefully documented their results (4). Informa-
tion was informally exchanged at small demonstration
courses and prospective registries were published (5).
The late 1980s saw an explosion in popularity of PTCA.
Formal interventional fellowship programs were formed,
and dramatic advances in imaging equipment and dramatic
improvements in flexibility and steerability of catheters
occurred. By 1990, 500,000 patients a year were being
treated with PTCA. These accomplishments occurred with-
out the benefit of randomized clinical trials (RCTs). The
first RCT of angioplasty therapy validated its use in acute
infarction (6). The predominant indication for angioplasty
in the 1980s was for treatment of symptomatic angina. A
RCT of angioplasty for symptomatic angina was not pub-
lished until 1992, or 15 years after the inception of the
technique (7). Shortly after this study, comparisons of
angioplasty to coronary artery bypass graft surgery for
treatment of multivessel disease occurred (8). By the time
balloon angioplasty was subjected to formal, randomized
comparison, it was a mature discipline with large numbers
of trained operators, excellent refined equipment and a large
data base for intelligent patient selection and periprocedural
management. A simple question must be asked: Was society
harmed or benefitted by the way in which coronary balloon
angioplasty was developed and validated? The reason this
fundamental question must be asked is because this proved,
successful method for new device development may never be
repeated.
Imagine a young Andreas Gruentzig trying to introduce
coronary angioplasty in 1999 rather than 1979. Two major
hurdles would assuredly thwart his efforts. First, federal
regulations would place enormous road blocks. Extensive
animal testing would be required. Not only would acute
animal safety experiments be required but long-term healing
data would also be needed. The expense of this extensive
preclinical testing data would mandate venture capital fund-
ing. This in turn would place enormous time pressures for
start and completion of RCTs. Today the RCT completion
is imperative because without it, no insurance coverage for
hospital stay or reimbursement for catheter costs would
occur. Thus, in 1999, a young Gruentzig would quickly lose
control of his idea and be totally stymied by regulatory road
blocks. In addition, his new idea would be forced into
immediate randomized comparisons. Imagine using the
original Gruentzig balloon catheter today in comparison to
single-vessel bypass! Balloon angioplasty would never have
been validated and developed; atherectomy would never
have existed; and coronary stent implantation would not
have its delivery platform. Again, the fundamental question
must be asked: Was society harmed or benefitted by the way
in which coronary balloon angioplasty was developed?
In this issue of the Journal, Tsuchikane et al. (9) report
the final results of the STent versus Directional Coronary
Atherectomy Randomized Trial (START). The operators
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use an aggressive debulking technique guided by intravas-
cular ultrasound to obtain results superior to elective stent
implantation. The START investigators have proceeded
with a line of investigation that has formally tested direc-
tional atherectomy in three previous RCTs. These RCTs
were conducted only after a large experience base of clinical
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use of this device occurred (10). The superb initial and
long-term results from START are not only a testament to
the excellent skills of the START investigators, but also
show a maturation of the directional atherectomy technique.
With each subsequent RCT, lumen stenosis has decreased
and target lesion revascularization rates have fallen (Fig. 1).
At the time of the original RCT (Coronary Angioplasty
Versus Excisional Atherectomy Trial [CAVEAT]), contro-
versy existed about how aggressive one should be with
atherectomy. Concern had been voiced based on animal
(11) and clinical (12) series that deep, subintimal resection
would accelerate restenosis. Thus in the CAVEAT study, a
conservative strategy was used with 5F and 6F catheters in
53% of cases, and a final residual stenosis of 29% was
achieved. Careful analysis of atherectomy biopsy samples
from the CAVEAT I and II trials in fact refuted the
relation between depth of tissue resection and restenosis
(13). On the basis of the unimpressive results of CAVEAT
I and armed with the superb CAVEAT histologic data, the
Balloon vs. Optimal Atherectomy Trial (BOAT) investiga-
tors (14) later clearly demonstrated that an aggressive
debulking technique could result in lower residual stenosis
and lower restenosis rates as compared with balloon angio-
plasty. In the BOAT trial, 7F cutters were used in 95% of
cases and balloon postdilation was used in 81% of cases. As
a result, final lumen stenosis was 15%. As a consequence of
this aggressive debulking, angiographic restenosis was sig-
nificantly lower for atherectomy than for balloon angio-
plasty. Further armed with these encouraging BOAT re-
sults, the START investigators used an even more
aggressive debulking strategy. Seven French cutters were
used in 65% of cases and 7F graft cutters were used in 35%
of cases. High pressure balloon inflations were used to
obtain a 1.1:1 balloon to artery ratio. In fact, 27% of cases
had 4.0-mm balloons used after dilation. Presumably be-
cause of the use of intravascular ultrasound guidance, no
coronary perforations occurred. A final residual stenosis of
13% was achieved, and this was associated with lower
angiographic and clinical restenosis rates than with routine
stent implantation. Since the completion of START, a
mature discipline of directional atherectomy exists. Indica-
tions are well established for lesions not well suited for stent
implantation such as ostial left anterior descending coronary
artery or true bifurcation lesions. Directional atherectomy
may be the procedure of choice for these lesions. The major
scientific underpinning for directional atherectomy, includ-
ing all the randomized trials, was obtained after federal
approval and commercial availability. Was society harmed
by this method of device development?
Imagine a young John Simpson attempting to develop
directional atherectomy today. Again, animal testing re-
quirements would be exhaustive. Even more daunting
would be that the entire cost of the hospital stay for a patient
treated with directional atherectomy would need to be borne
by the device company. Assuming an average procedural
cost of $10,000, and assuming that 512 patients would be
randomized to atherectomy (the number in CAVEAT), a
minimum of $5 to $10 million would be required for
hospital costs alone. The fact that the CAVEAT results are
viewed as largely disappointing, with marginal restenosis
benefit and higher one-year mortality occurring for the
atherectomy group is even more disturbing (15). On the
basis of these results, it is certain that directional atherec-
tomy would have been abandoned. Thus, a useful, safe
medical device would never have been available for clinical
use.
In retrospect, the development of coronary balloon an-
gioplasty and coronary atherectomy has taught us invaluable
lessons on how medical devices can be safely and fruitfully
developed. A sequence of initial operator experience, device
refinement, large practice experience and ultimately timely
conduct of randomized trials is mandatory. Premature
conduct of randomized trials before devices are refined,
before operators are proficient or before optimal techniques
are established can jeopardize development of safe, useful
products. Imagine forcing the conduct of an RCT for the
original unsheathed Palmaz-Shatz stent (Johnson & John-
son, Warren, New Jersey). The device was rigid, fraught
with risk of embolization and associated with the exorbitant
risk of subacute thrombosis. Had such a premature RCT
been conducted, it is likely that the study would have been
stopped prematurely on ethical safety concerns. Thus, the
Figure 1. A, Percent diameter stenosis (DS) after directional
atherectomy in the four published randomized trials. B, Influence
of final residual stenosis on target lesion revascularization (TLR)
rates. BOAT 5 Balloon Versus Optimal Atherectomy Trial;
CAVEAT 5 Coronary Angioplasty Versus Excisional Atherec-
tomy Trial; CCAT 5 Canadian Coronary Atherectomy Trial;
START 5 STent Versus directional Atherectomy Randomized
Trial.
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mainstay of today’s interventional armamentarium would
not have been developed.
This risk of premature conduct of randomized trials is in
fact occurring today for innovative revascularization tech-
niques. Percutaneous direct myocardial revascularization
was forced into early trials before sufficient operators were
trained, before large experience on optimal technique oc-
curred and with crude clinical “model A” devices. Random-
ized trials of beta radiation are occurring before dosing
protocols and catheter placement protocols are refined. If
these initial randomized trials are negative, will these
potentially promising devices be abandoned? Unfortunately,
government approval and insurance reimbursement are now
directly tied to completion of randomized trials. As a
consequence, it is likely that the pace of medical device
invention will dramatically slow or even cease in the U.S. At
the time that Gruentzig and Simpson attempted to develop
their initial devices, all that was required for approval was
documentation of successful treatment of 75 cases with six
months of clinical follow up. Is society really better off today
with the extraordinarily complex and cumbersome regula-
tions that exist for medical device evaluation?
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